Boston Scientific (NYSE:BSX) Stock Price Target Lowered at Sanford C. Bernstein

Key Points

• Sanford C. Bernstein lowered Boston Scientific’s price target from $54 to $49 while maintaining an “outperform” rating, implying approximately 14.8% upside from the stock’s $42.69 price.
• Analyst sentiment remains broadly positive, with MarketBeat reporting a “Moderate Buy” consensus and an average price target of $61.87, despite several firms lowering targets and issuing neutral or sell ratings.
• Boston Scientific’s quarterly revenue exceeded expectations and EPS matched estimates, but an eight-day cybersecurity outage, weaker demand in some businesses, pricing pressure in China and softer margins led the company to reduce its outlook.

Boston Scientific (NYSE:BSX - Get Free Report) had its price objective reduced by stock analysts at Sanford C. Bernstein from $54.00 to $49.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has an "outperform" rating on the medical equipment provider's stock. Sanford C. Bernstein's price target would indicate a potential upside of 14.79% from the company's current price.

Several other equities analysts have also recently issued reports on the stock. Robert W. Baird lifted their price objective on shares of Boston Scientific from $50.00 to $51.00 and gave the stock an "outperform" rating in a research note on Thursday. Weiss Ratings reiterated a "sell (d+)" rating on shares of Boston Scientific in a research note on Friday, October 2nd. Citigroup cut their price target on Boston Scientific from $48.00 to $44.00 and set a "neutral" rating for the company in a report on Thursday. Wells Fargo & Company lowered their price objective on Boston Scientific from $48.00 to $45.00 and set an "equal weight" rating on the stock in a research report on Thursday. Finally, Piper Sandler dropped their price objective on shares of Boston Scientific from $65.00 to $60.00 and set an "overweight" rating for the company in a report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Boston Scientific presently has an average rating of "Moderate Buy" and an average target price of $61.87.

Boston Scientific Stock Performance

Boston Scientific stock traded up $0.26 during mid-day trading on Thursday, hitting $42.69. 31,748,900 shares of the company's stock traded hands, compared to its average volume of 18,738,809. Boston Scientific has a one year low of $39.57 and a one year high of $105.65. The company has a market cap of $61.86 billion, a PE ratio of 17.28, a price-to-earnings-growth ratio of 1.10 and a beta of 0.58. The firm has a 50 day moving average price of $45.12 and a 200 day moving average price of $57.43. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, meeting analysts' consensus estimates of $0.73. The company had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.07 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The company's quarterly revenue was up 1.4% compared to the same quarter last year. During the same period last year, the company earned $0.75 earnings per share. On average, equities analysts forecast that Boston Scientific will post 3.21 EPS for the current year.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael Mahoney purchased 186,240 shares of the stock in a transaction on Monday, August 3rd. The shares were purchased at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the transaction, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Edward Ludwig bought 5,000 shares of the business's stock in a transaction dated Friday, July 31st. The shares were bought at an average price of $45.48 per share, with a total value of $227,400.00. Following the purchase, the director owned 30,359 shares in the company, valued at $1,380,727.32. The trade was a 19.72% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders have bought 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of BSX. BlackRock Inc. bought a new stake in Boston Scientific during the 2nd quarter worth approximately $5,534,781,000. Primecap Management Co. CA acquired a new position in Boston Scientific in the second quarter valued at about $2,156,233,000. Janus Henderson Group PLC raised its holdings in shares of Boston Scientific by 31.0% during the first quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider's stock worth $1,035,202,000 after acquiring an additional 3,907,981 shares during the period. Amundi grew its stake in shares of Boston Scientific by 13.8% in the first quarter. Amundi now owns 14,122,913 shares of the medical equipment provider's stock valued at $886,213,000 after buying an additional 1,707,754 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its stake in Boston Scientific by 25.9% in the first quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider's stock valued at $871,702,000 after buying an additional 2,856,040 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported third-quarter revenue of $5.138 billion, above the $5.07 billion consensus estimate, while adjusted EPS of $0.73 matched expectations. Management also highlighted new clinical-trial activity and FDA clearances for StoneSmart and SEISMIQ technologies. Boston Scientific announces results for third quarter 2026
• Positive Sentiment: Several analysts continue to see long-term upside despite cutting estimates. UBS, BTIG and Needham retained “buy” ratings, while Robert W. Baird raised its target to $51 and maintained an “outperform” rating. Analysts revise forecasts after Q3 results
• Neutral Sentiment: Management remains confident in Boston Scientific’s long-term strategy, but expects a recovery period and has described 2027 as a challenging transition year, with growth potentially flat before longer-term expansion.
• Negative Sentiment: An eight-day cybersecurity outage reduced third-quarter sales by approximately $150 million and continues to disrupt operations and customer activity. The company cut its full-year 2026 outlook to roughly 4.25% reported sales growth and forecast fourth-quarter reported and organic sales declines of 1% to 3%. Boston Scientific: 3 Key Takeaways for Long-Term Investors
• Negative Sentiment: Investors are also concerned about weaker electrophysiology and WATCHMAN demand, China pricing pressure and softer margins. Analysts including Oppenheimer and JPMorgan downgraded the stock, while Wells Fargo and other firms lowered price targets.

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.